Sirolimus-eluting balloon offers potential “paradigm shift” in restenosis treatment
Treatment provided a promising alternative to standard care in repeat percutaneous coronary interventions in the first-of-a-kind trial.
List view / Grid view
Treatment provided a promising alternative to standard care in repeat percutaneous coronary interventions in the first-of-a-kind trial.
Approval provides continuity of care into adulthood for patients with neurofibromatosis type 1 (NF1) using Koselugo (selumetinib) to manage symptoms.
Deal to advance potential first-in-class RNA therapeutics focused on genetic neuromuscular diseases such as Duchenne muscular dystrophy.
Results from the phase III study signify a successful collaboration with biopharma firm Incyte.
New findings support use of salbutamol MDI formulation in the next-generation low carbon propellant as a more sustainable option for patients with respiratory disease.
The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.
Merck & Co’s anti-PD-1 immunotherapy showed evidence at ESMO of its ability to prevent cancer recurrence in Merkel cell carcinoma.
Establishes Resource for AI Science in Europe and eyes frontier AI models and autonomous agentic AI for pharma.
The study is one of three to start, along with those in hidradenitis suppurativa and radiographic axial spondyloarthritis.
Offers potential symptomatic relief for cancer patients with chemotherapy-induced peripheral neuropathy (CIPN).
Companies’ first-line ambitions for the antibody drug conjugate buoyed by the TROPION-Breast02 clinical trial.
The company will instead focus its attention on advancing candidates for modalities that include biologics and ADCs.
Despite progress from AstraZeneca, Sanofi, Merck & Co, GSK and Pfizer, analysts say effective respiratory syncytial virus treatments are still needed.
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
uniQure’s positive topline data “are the most convincing in the field to date” and indicate the gene therapy’s potential disease-modifying effects.